Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

Sponsor
Janssen Research & Development, LLC
Study ID
NCT05161598
Status
No Longer Available

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Teclistamab — DRUG
    Teclistamab will be administered subcutaneously (SC).

Study Details

Teclistamab pre-approval access in relapsed or refractory multiple myeloma.

Key Dates

Status verified
Dec 2025

Related Studies